The PAXgene urine liquid biopsy kit is designed for use with various molecular diagnostic platforms. Credit: angellodeco / Shutterstock.

PreAnalytiX has introduced the PAXgene urine liquid biopsy set, which enables cell-free DNA (cfDNA) analysis from urine with molecular testing technologies.

The company is a joint venture between Qiagen and BD.

Related Company Profiles

View all

The biopsy set is designed to overcome the challenges associated with cfDNA degradation, offering a verified, standardised preanalytical workflow.

Urine cfDNA is increasingly recognised for its potential in research and future clinical applications. It provides a non-invasive means to detect genetic modifications and generate genomic data not found in blood samples.

The rapid degradation of cfDNA in urine samples has posed significant challenges for accurate analysis. The PAXgene urine liquid biopsy set is poised to change this, providing a method for urine collection and cfDNA stabilisation.

See Also:

Qiagen MDx Development Sample Technologies head and PreAnalytiX Management Committee co-chair Dr Uwe Oelmueller said: “With the innovative PAXgene urine liquid biopsy set, we are excited to address a pressing market need for a urine collection, stabilisation, transport and storage device that is integrated into a complete preanalytical workflow for the development of cfDNA-based tests.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The product is compatible with a range of molecular testing technologies, such as qPCR, digital PCR, and next-generation sequencing (NGS), and will be commercialised by Qiagen.

The PAXgene urine liquid biopsy set offers a closed configuration for urine collection and stabilisation of cfDNA, supporting various sample shipment and storage conditions.

It aligns with Europe’s latest CEN/TS standard for preanalytical urine handling for isolated cell-free DNA.

This launch complements Qiagen’s portfolio of liquid biopsy solutions, which cover a broad spectrum of analytes and molecular detection technologies.

In March 2023, Qiagen collaborated with Servier to develop a companion diagnostic test for the IDH1 inhibitor, Tibsovo, which is indicated for the treatment of the blood cancer acute myeloid leukaemia.